Johnson & Johnson (NYSE:JNJ) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On March 2, BofA ...
Johnson & Johnson (JNJ) announced on Friday the achievement of a primary safety endpoint in a Phase 1 trial for a drug ...
The fair value estimate for Johnson & Johnson has been adjusted from US$232.50 to US$237.29 per share, a small move that ...
Zacks Investment Research on MSN
Johnson & Johnson (JNJ) could be a great choice
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent ...
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...
Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.
The market’s fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month. Consumer sentiment sits at 56.4 on the University of Michigan index, deep in ...
Johnson & Johnson’s position as a diversified healthcare leader continues to attract attention within equity markets. Through ...
Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $21.9 ...
March 4 (Reuters) - Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either ...
Johnson & Johnson (JNJ), Chevron (CVX), Realty Income (O), Broadcom (AVGO), and Agree Realty (ADC) for income investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results